肝性脳症(HE)治療薬の世界市場2018-2022:NAD、抗生物質、その他

◆英語タイトル:Global Hepatic Encephalopathy (HE) Therapeutics Market 2018-2022
◆商品コード:IRTNTR20766
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年2月6日
◆ページ数:102
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

Technavio社が発行した当調査レポートでは、肝性脳症(HE)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、肝性脳症(HE)治療薬の世界市場規模及び予測、製品別分析、地域別分析/市場規模、主要国別分析、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況などの情報をお届けいたします。Technavio社は肝性脳症(HE)治療薬の世界市場が2018-2022年期間中に年平均5.35%成長すると予測しています。当レポート上に記載されている主な企業は、ASKA Pharmaceutical、COSMO PHARMACEUTICALS、Mallinckrodt、Valeant等です。

・エグゼクティブサマリー
・肝性脳症(HE)治療薬の世界市場:市場概観
・肝性脳症(HE)治療薬の世界市場:業界の構造分析
・肝性脳症(HE)治療薬の世界市場:市場規模及び予測
・肝性脳症(HE)治療薬の世界市場:製品別分析
・肝性脳症(HE)治療薬の世界市場:地域別分析
・肝性脳症(HE)治療薬の世界市場:アジア市場規模
・肝性脳症(HE)治療薬の世界市場:アメリカ市場規模
・肝性脳症(HE)治療薬の世界市場:ヨーロッパ市場規模
・肝性脳症(HE)治療薬の世界市場:主要国別分析
・肝性脳症(HE)治療薬の世界市場:成長要因
・肝性脳症(HE)治療薬の世界市場:課題
・肝性脳症(HE)治療薬の世界市場:製品パイプライン分析
・肝性脳症(HE)治療薬の世界市場:市場動向
・肝性脳症(HE)治療薬の世界市場:競争状況
...

※上記の和訳は最新内容ではない場合があります。
【レポートの概要】

About Hepatic Encephalopathy (HE) Therapeutics
HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.

Technavio’s analysts forecast the global hepatic encephalopathy (HE) therapeutics market to grow at a CAGR of 5.35% during the period 2018-2022.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global hepatic encephalopathy (HE) therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Hepatic Encephalopathy (HE) Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• ASKA Pharmaceutical
• COSMO PHARMACEUTICALS
• Mallinckrodt
• Valeant

[Market driver]
• Availability of patient-focused programs to assist disease management
• For a full, detailed list, view our report

[Market challenge]
• Late and inaccurate diagnosis
• For a full, detailed list, view our report

[Market trend]
• Technological advances
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
• Market outline

PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 08: PIPELINE ANALYSIS

PART 09: MARKET SEGMENTATION BY PRODUCT
• Overview
• Comparison by product
• NADs
• Antibiotics
• Others
• Market opportunity by product

PART 10: MARKET SEGMENTATION BY DISEASE SEVERITY
• Overview
• CHE
• OHE

PART 11: CUSTOMER LANDSCAPE

PART 12: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas
• EMEA
• APAC
• Key leading countries
• Market opportunity

PART 13: DECISION FRAMEWORK

PART 14: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 15: MARKET TRENDS
• Technological advances
• Emergence of novel treatment targets

PART 16: VENDOR LANDSCAPE
• Overview
• Landscape disruption

PART 17: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ASKA Pharmaceutical
• COSMO PHARMACEUTICALS
• Mallinckrodt
• Valeant

PART 18: APPENDIX
• List of abbreviations

[List of Exhibits] Exhibit 01: Interorgan ammonia metabolism in healthy liver
Exhibit 02: WHC classification of HE
Exhibit 03: Recommended treatment pathway for HE
Exhibit 04: Parent market
Exhibit 05: Global CNS disorders drugs market: Segments
Exhibit 06: Market characteristics
Exhibit 07: Global HE therapeutics market: Segments
Exhibit 08: Market definition: Inclusions and exclusions checklist
Exhibit 09: Market size 2017
Exhibit 10: Validation techniques employed for market sizing 2017
Exhibit 11: Global HE therapeutics market 2017-2022 ($ millions)
Exhibit 12: Global HE therapeutics market: Year-over-year growth 2018-2022 (%)
Exhibit 13: Five forces analysis 2017
Exhibit 14: Five forces analysis 2022
Exhibit 15: Bargaining power of buyers
Exhibit 16: Bargaining power of suppliers
Exhibit 17: Threat of new entrants
Exhibit 18: Threat of substitutes
Exhibit 19: Threat of rivalry
Exhibit 20: Market condition: Five forces 2017
Exhibit 21: Pipeline landscape by development phase
Exhibit 22: Key clinical trials
Exhibit 23: Global HE therapeutics market: Segmentation by product 2017-2022 (%)
Exhibit 24: Comparison by product
Exhibit 25: Global NAD HE therapeutics market 2017-2022 ($ millions)
Exhibit 26: Global NAD HE therapeutics market: Year-over-year growth 2018-2022 (%)
Exhibit 27: Global antibiotic HE therapeutics market 2017-2022 ($ millions)
Exhibit 28: Global antibiotic HE therapeutics market: Year-over-year growth 2018-2022 (%)
Exhibit 29: Global other HE therapeutics market 2017-2022 ($ millions)
Exhibit 30: Global other HE therapeutics market: Year-over-year growth 2018-2022 (%)
Exhibit 31: Market opportunity by product
Exhibit 32: Customer landscape
Exhibit 33: Global HE therapeutics market: Segmentation by geography 2017-2022 (%)
Exhibit 34: Regional comparison
Exhibit 35: HE therapeutics market in Americas 2017-2022 ($ millions)
Exhibit 36: HE therapeutics market in Americas: Year-over-year growth 2018-2022 (%)
Exhibit 37: HE therapeutics market in EMEA 2017-2022 ($ millions)
Exhibit 38: HE therapeutics market in EMEA: Year-over-year growth 2018-2022 (%)
Exhibit 39: HE therapeutics market in APAC 2017-2022 ($ millions)
Exhibit 40: HE therapeutics market in APAC: Year-over-year growth 2018-2022 (%)
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: ASKA Pharmaceutical: Overview
Exhibit 49: ASKA Pharmaceutical: Business segments
Exhibit 50: ASKA Pharmaceutical: Organizational developments
Exhibit 51: ASKA Pharmaceutical: Segment focus
Exhibit 52: ASKA Pharmaceutical: Key offerings
Exhibit 53: ASKA Pharmaceutical: Key customers
Exhibit 54: COSMO PHARMACEUTICALS: Overview
Exhibit 55: COSMO PHARMACEUTICALS: Business segments
Exhibit 56: COSMO PHARMACEUTICALS: Organizational developments
Exhibit 57: COSMO PHARMACEUTICALS: Segment focus
Exhibit 58: COSMO PHARMACEUTICALS: Key offerings
Exhibit 59: COSMO PHARMACEUTICALS: Key customers
Exhibit 60: Mallinckrodt: Overview
Exhibit 61: Mallinckrodt: Business segments
Exhibit 62: Mallinckrodt: Organizational developments
Exhibit 63: Mallinckrodt: Geographic focus
Exhibit 64: Mallinckrodt: Segment focus
Exhibit 65: Mallinckrodt: Key offerings
Exhibit 66: Mallinckrodt: Key customers
Exhibit 67: Valeant: Overview
Exhibit 68: Valeant: Business segments
Exhibit 69: Valeant: Organizational developments
Exhibit 70: Valeant: Geographic focus
Exhibit 71: Valeant: Segment focus
Exhibit 72: Valeant: Key offerings
Exhibit 73: Valeant: Key customers



【掲載企業】

ASKA Pharmaceutical, COSMO PHARMACEUTICALS, Mallinckrodt, and Valeant.

【リサーチ方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 肝性脳症(HE)治療薬の世界市場2018-2022:NAD、抗生物質、その他(Global Hepatic Encephalopathy (HE) Therapeutics Market 2018-2022)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆